<DOC>
	<DOCNO>NCT00596557</DOCNO>
	<brief_summary>The different mechanism action Everolimus cyclosporine suppress immune function synergistic manner . Thus postulate use Everolimus combination cyclosporine permit significant cyclosporine dose reduction without loss immunosuppressive activity clinical setting . The aim present study evaluate evolution renal function initiation Everolimus minimalisation CNI dose .</brief_summary>
	<brief_title>Everolimus Low Dose CNI Compared With MMF Full CNI Dose Heart Transplanted Patients : One Year Follow</brief_title>
	<detailed_description>Everolimus new proliferation signal inhibitor immunosuppressive antiproliferative activity . The mechanism action Everolimus distinct calcineurin inhibitor . Cardiac allograft vasculopathy major cause late death cardiac transplant patient . The different mechanism action Everolimus cyclosporine suppress immune function synergistic manner . Thus postulate use Everolimus combination cyclosporine permit significant cyclosporine dose reduction without loss immunosuppressive activity clinical setting . The aim present study evaluate evolution renal function initiation Everolimus minimalisation CNI dose .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age ≥ 18 year Signed informed consent 6 month 15 year heart transplantation Stable heart allograft function without rejection least 12 month Same immunusuppressive drug least 3 month CNI base immunusuppression , Cyclosporin level C0 100200 ng/ml FK level 510 ng/ml preserve CNI level . Poor renal function : creatinine &gt; 1.5 mg % . Suspected noncompliance Intolerance Everolimus Life expectancy &lt; 1year Proteinuria &gt; 1.5 g/24u/1.73m2 Previous sirolimus treatment Patients receive investigational drug Patients platelet count &lt; 50,000/mm³ baseline . Presence severe hypercholesterolemia ( ≥350 mg/dL ; ≥9 mmol/L ) hypertriglyceridemia ( ≥750 mg/dL ; ≥8.5 mmol/L ) Patients absolute neutrophil count ≤ 1,500/mm3 white blood cell count ≤ 4000/mm³ baseline Patients know hypersensitivity similar drug component formulation Patients treated terfenadine , astemizole , cisapride . Patients treat drug strong inducer inhibitor cytochrome P450 3A4 . Patients past ( within past 5 year ) present malignancy ( excise basal cell carcinoma ) Patients clinically significant systemic infection . Existence surgical medical condition , opinion investigator , might significantly alter absorption , distribution , metabolism excretion study medication , and/or presence severe diarrhea active peptic ulcer . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Renal function , heart transplant , everolimus</keyword>
</DOC>